The biologics market was valued at USD 419.07 billion in 2023 and is projected to grow significantly, reaching approximately USD 845.78 billion by 2033. This growth is expected to occur at a Compound Annual Growth Rate (CAGR) of 7.6% through 2032.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5108
Biologics Market Report Highlights:
- The biologics market size ballooned to a staggering USD 419.07 billion in 2023.
- It is anticipated to attain USD 845.78 billion by 2033.
- It is expected to register 7.6% of CAGR by 2032.
- Blood and blood products led the market in 2023, capturing a commanding 66% market share.
- Oncology takes center stage, with this application segment leading the pack at 36% share in 2023.
- Asia Pacific is the rising star, predicted to be the fastest-growing region over the next decade.
The American Cancer Society estimates 1.92 million new cancer cases and 609,360 deaths in the U.S., contributing to a global toll of 9.6 million lives lost in 2022. Biologics, monoclonal antibodies, and immunotherapies revolutionize cancer care, boosting survival and minimizing side effects.
Biologics are therapeutic products derived from living organisms or their components, such as cells, proteins, or nucleic acids. Unlike traditional drugs, which are often chemically synthesized, biologics are typically large and complex molecules produced using advanced technologies like genetic engineering. This complexity allows them to closely mimic the natural substances in the human body, making them more targeted and specific in their actions. One significant aspect of biologics is their role in treating diseases at the molecular and cellular levels. They are designed to interact with specific biological pathways and mechanisms, making them highly effective in addressing the underlying causes of various diseases. This targeted approach can result in better treatment outcomes and, in many cases, fewer adverse effects than conventional drugs.
The application of biologics spans a wide range of therapeutic areas. One prominent example is their use in oncology. Monoclonal antibodies, a biologic, have revolutionized cancer treatment by selectively targeting cancer cells while sparing healthy cells. This targeted action helps minimize damage to surrounding tissues and reduces side effects commonly associated with traditional chemotherapy. In autoimmune disorders, where the immune system mistakenly attacks the body’s tissues, biologics can modulate specific immune response components. This helps to restore the balance and alleviate symptoms without suppressing the entire immune system, as is often the case with conventional treatments.
The growth of the biologics market is fueled by ongoing advancements in biotechnology, such as improved techniques for protein engineering and manufacturing processes. These innovations enable the development of novel and more sophisticated biological therapies. It’s important to note that biologics often come with higher production costs and can be more challenging to manufacture than small-molecule drugs. This can result in higher prices for biological treatments. Despite this, the demand for biologics continues to rise due to their ability to provide effective and often life-changing solutions for patients facing various health challenges.
Recent Developments
- In May 2024, using a seed investment of €16 million ($17.2 million), Commit Biologics came out of stealth to develop antibody therapies for the treatment of cancer and autoimmune diseases using their bispecific complement engaging (BiCE) technology. The primary investors were Novo Nordisk’s holding and investment business, Novo Holdings, and the European venture capital firm Bioqube Ventures.
- In March 2024, Bone Biologics, a company that specializes in spine fusion implants, announced an IPO for $2 million. According to a news release dated March 4, the public offering consists of 781,251 shares of the company’s common stock, which is priced at $2.56 per share. According to the firm, the funds obtained would go toward funding clinical research, working capital, general corporate goals, and its portfolio of patents.
- In January 2024, the biosimilar ranibizumab Cimerli (ranibizumab-earn) will be acquired by Sandoz and Coherus BioSciences for an upfront cash acquisition price of $170 million. This includes a product inventory, ophthalmology-specific sales and reimbursement staff, access to exclusive commercial tools, and the ability to apply for a biologics license.
- In April 2023, the biopharmaceutical company TORL BioTherapeutics LLC, which focuses on developing innovative biologics for cancer therapy, announced the completion of a $158 million Series B funding and its official debut. In the laboratory of scientific co-founder Dennis Slamon, who is chairman of the hematology/oncology division and a medical professor at UCLA’s David Geffen School of Medicine (DGSOM), the company’s antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) were discovered.
- In 2020, WuXi Biologics bought Bayer’s drug manufacturing facility in Germany, marking its first facility in Europe. This move aimed to boost WuXi Biologics’ ability to produce medications commercially.
- In October 2020, Cadila Pharmaceuticals introduced two similar biologic drugs, NuPTH and Cadalimab, in the Indian market. This step was taken to expand the company’s presence in different regions.
Biologics Market Companies
- Amgen
- Merck & Co.
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb
- Sanofi
- Bayer AG
- AstraZeneca
- GlaxoSmithKline Plc.
- Novartis AG
- Eli Lilly and Company
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/biologics-market-size
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5108
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare